【摘要】 目的：观察消栓肠溶胶囊（XSECC）治疗脑梗死的临床疗效，探索其可能的作用机制。方法：急性缺血性脑卒中（AIS）气虚血瘀型患者被随机分配到对照组和观察组。在第0天、第14天、第30天和第90天，使用美国国立卫生研究院卒中量表（NIHSS）、日常生活活动量表（ADL）、Hachinski缺血量表（HIS）、Barthel指数（BI）、临床疗效评分和中医证候评分对患者进行评估。此外，在第30天和第90天测量了VEGF和BDNF水平。最后，分析两组中每个量表评分和血管神经因子的变化。结果：治疗14天后，观察组在NIHSS、ADL和BI的差异值上均高于对照组，并且中医证候和临床疗效评分也有所增加（P <0.05）。治疗30天后，NIHSS、ADL、HIS和中医证候评分与对照组相比有所下降，而BI和临床疗效评分则有所增加（P<0.05）。90天后，观察组在ADL的差异值上高于对照组，并且中医证候评分也有所增加（P=0.047,P=0.005）。在第14天、第30天和第90天，观察组的VEGF和BDNF水平高于对照组（P<0.05）。第0天的VEGF和BDNF水平与急性缺血性中风患者的预后相关；因此，它们对急性脑梗死的预后具有预测价值。结论：联合消栓肠溶胶囊治疗可以改善急性和复发性脑梗死患者的临床疗效。其作用机制可能与促进血管内皮生长因子（VEGF）和脑源性神经营养因子（BDNF）的分泌有关。更多还原

【Abstract】 Objective: To explore the clinical efficacy of Xiaoshuan enteric-coated capsule(XSECC) in treating cerebral infarction and its potential mechanism of action.Methods: Patients with acute ischemic stroke(AIS) of the qi deficiency and blood stasis type were randomly assigned to the control and observation groups. They were evaluated using the National Institutes of Health Stroke Scale(NIHSS), Activities of Daily Living(ADL), Hachinskilnchemic Scale(HIS),Barthel Index(BI), clinical efficacy scores, and TCM syndrome scores on days 0, 14, 30, and 90.Furthermore, VEGF and BDNF levels were measured on days 30 and 90. Finally, we analyzed the changes in each scale score and vascular neurological factor in both groups.Results: After 14 days of treatment, the difference values in NIHSS, ADL, and BI were higher, and TCM syndrome and clinical efficacy scores were increased in the observation group compared with those of the control group(all P <.05). After 30 days, the NIHSS, ADL, HIS, and TCM syndrome scores were decreased compared with those of the control group, while BI and clinical efficacy scores were increased(all P <.05). After 90 days, the difference value in ADL was higher, and TCM syndrome score was increased in the observation group compared with that of the control group(P =.047, P =.005,respectively). The levels of VEGF and BDNF were higher in the observation group than in the control group on days 14, 30, and 90(all P <.05). VEGF and BDNF levels on day 0 were associated with prognosis of patients with AIS; therefore, they have a predictive value for the prognosis of acute cerebral infarction.Conclusions: XSECC therapy can improve clinical outcomes in patients with acute and recurrent cerebral infarctions. Its mechanism of action may be associated with the secretion of VEGF and BDNF.更多还原